Human papillomavirus infection and the primary and secondary prevention of cervical cancer
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
A wealth of evidence has led to the conclusion that virtually all cases of cervical cancer are attributable to persistent infection by a subset of human papillomavirus (HPV) types, especially HPV type 16 (HPV-16) and HPV-18. These HPV types also cause a proportion of other cancers, including vulvar, vaginal, anal, penile, and oropharyngeal cancers. Although cervical cancer screening, primarily with the Papanicolaou (Pap) smear, has reduced the incidence of this cancer in industrialized countries, cervical cancer remains the second most common cause of death from cancer in women worldwide, because the developing world has lacked the resources for widespread, high-quality screening. In addition to advances in Pap smear technology, the identification of HPV as the etiologic agent has produced 2 recent advances that may have a major impact on approaches to reduce the incidence of this disease. The first is the development of a preventive vaccine, the current versions of which appear to prevent close to 100% of persistent genital infection and disease caused by HPV-16 and HPV-18; future second-generation vaccines may be able to protect against oncogenic infections by a broader array of HPV types. The second is the incorporation of HPV testing into screening programs. In women aged >30 years, HPV testing can identify high-grade cervical intraepithelial neoplasia earlier than Pap smears with acceptable rates of specificity. These results, together with the high sensitivity of HPV testing, suggest that such testing could permit increased intervals for screening. An inexpensive HPV test in development, if successful, may be incorporated as part of an economically viable 'screen-and-treat' approach in the developing world. The manner in which vaccination and screening programs are integrated will need to be considered carefully so that they are efficient in reducing the overall incidence of cervical cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886 · cited 1×
“CIN-21 MITT GSK* Harper 2006(55) 5/470 0/481 100 (27-100) MITT GSK Paavonen 2007(51) 21/7838 2/7788 90 (53-99) ATP Mercky Garland 2007(52) 44/2258 0/2241 ATP Merck FUTURE II Study Group 58 42/5260 1/5305 98 (86-100) CIN-11 MITT GSK Harper 2006(55) 8/470 0/481 100 (42-100) MITT GSK Paavonen 2007(51) 28/7838 3/7788 89 (…”
Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women
Winer, R. L., Hughes, J. P., Feng, Q., O'Reilly, S., Kiviat, N. B., Holmes, K. K., & Koutsky, L. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053284 · Cited by 694
Cost-Effectiveness of Cervical-Cancer Screening in Five Developing Countries
Goldie, S. J., Gaffikin, L., Goldhaber-Fiebert, J. D., Gordillo-Tobar, A., Levin, C., Mahé, C., & Wright, T. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa044278 · Cited by 671
Management of women who test positive for high-risk types of human papillomavirus: the HART study
Cuzick, J., Szarewski, A., Cubie, H., Hulman, G., Kitchener, H., Luesley, D., McGoogan, E., Menon, U., Terry, G., Edwards, R., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14955-0 · Cited by 510 · cited 1×
“CIN-21 MITT GSK* Harper 2006(55) 5/470 0/481 100 (27-100) MITT GSK Paavonen 2007(51) 21/7838 2/7788 90 (53-99) ATP Mercky Garland 2007(52) 44/2258 0/2241 ATP Merck FUTURE II Study Group 58 42/5260 1/5305 98 (86-100) CIN-11 MITT GSK Harper 2006(55) 8/470 0/481 100 (42-100) MITT GSK Paavonen 2007(51) 28/7838 3/7788 89 (…”
Vaccarella, S., Franceschi, S., Herrero, R., Muñoz, N., Snijders, P. J. F., Clifford, G. M., Smith, J. S., Lazcano-Ponce, E., Sukvirach, S., Shin, H.-R., et al. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0577 · Cited by 202
Cited by
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases
Berman, T. A., & Schiller, J. T. (2017) · Cancer · doi:10.1002/cncr.30588 · Cited by 395
Self-citationSelf-assembling protein nanoparticles in the design of vaccines
López-Sagaseta, J., Malito, E., Rappuoli, R., & Bottomley, M. J. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.11.001 · Cited by 353
Polarimetric imaging of uterine cervix: a case study
Pierangelo, A., Nazac, A., Benali, A., Validire, P., Cohen, H., Novikova, T., Ibrahim, B. H., Manhas, S., Fallet, C., Antonelli, M.-R., et al. (2013) · Optics Express · doi:10.1364/oe.21.014120 · Cited by 255
White, E. A., Sowa, M. E., Tan, M. J. A., Jeudy, S., Hayes, S. D., Santha, S., Münger, K., Harper, J. W., & Howley, P. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116776109 · Cited by 198
“HPV16 in particular is found in 50% of cervical cancers (4).”
Background
Metadata
- Authors
- Lowy, D. R., Solomon, D., Hildesheim, A., Schiller, J. T., & Schiffman, M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-09-17
- Volume
- 113
- Issue
- S7
- Pages
- 1980-1993
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1974146156
- Cited by
- 157
- References
- 5
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.